Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday. Shares of Moderna ...

Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. Moderna faces significant commercial challenges, particularly in ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%.

We recently compiled a list of the These 10 Firms Were Last Week's Worst Performers. In this article, we are going to take a ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...